Skip to main content

Advertisement

Table 5 Child Health and Illness Profile-Child Edition, change from baseline based on data of the 3 placebo-controlled trials.

From: Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials

  Children (n = 275) Adolescents (n = 112)
CHIP-CE items Mean change (SE) Atomoxetine (n = 183) Placebo (n = 92) Atomoxetine (n = 72) Placebo (n = 40)
Total Score 4.60 (0.62) 2.06 (0.80) 5.40 (0.94) 2.48 (1.28)
Satisfaction Domain 2.11 (0.83) 2.18 (1.07) 2.88 (1.22) 2.19 (1.65)
Satisfaction With Health 0.40 (0.75) 2.06 (0.97) 1.29 (1.21) 2.57 (1.65)
Satisfaction With Self 3.45 (0.88) 1.84 (1.14) 3.84 (1.28) 1.21 (1.73)
Comfort Domain 2.47 (0.65) 1.34 (0.84) 2.57 (0.93) 1.33 (1.26)
Physical Comfort 0.68 (0.64) 1.53 (0.83) 0.91 (0.81) -0.01 (1.10)
Emotional Comfort 3.37 (0.76) 1.01 (0.99) 3.34 (0.97) 1.23 (1.31)
Restricted Activity 0.81 (0.67) 0.49 (0.88) 0.46 (1.20) 2.20 (1.63)
Risk Avoidance Domain 4.63 (0.64) 1.90 (0.82) 7.27 (0.93) 0.70 (1.28)
Individual Risk Avoidance 4.16 (0.67) 0.82 (0.86) 4.59 (1.15) -0.95 (1.56)
Threats to Achievement 4.08 (0.66) 2.12 (0.84) 7.35 (0.98) 1.53 (1.35)
Resilience Domain 3.20 (0.68) 1.23 (0.88) 1.00 (0.97) 1.69 (1.32)
Family Involvement 1.69 (0.70) 0.18 (0.91) 0.19 (1.00) 2.05 (1.35)
Physical Activity 1.08 (0.72) 1.16 (0.92) -2.15 (1.10) -0.42 (1.49)
Social Problem Solving 3.54 (0.77) 1.31 (0.99) 3.26 (1.12) 1.67 (1.56)
Achievement Domain 4.04 (0.60) 0.68 (0.79) 4.83 (0.86) 2.13 (1.21)
Academic Performance 4.03 (0.68) 1.01 (0.88) 5.21 (0.91) 2.00 (1.28)
Peer Relations 2.61 (0.57) 0.30 (0.74) 2.76 (0.80) 0.52 (1.09)
  1. All values are presented as LS Means (SE)
  2. Abbreviations: CHIP-CE, Child Health and Illness Profile-Child Edition; SE, standard error; LS, least square